Revista nº 817

Quintanilla Carrillo B, et al. | Tratamiento de la COVID-19 183 Actual Med.2023;108(817):166-184 38. Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, et al. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. J Steroid Biochem Mol Biol. 2020 Nov;204:105771. 39. Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D su- pplementation for COVID-19 disease: a randomised, pla- cebo-controlled, study (SHADE study). Postgrad Med J. 2020 Nov 12:postgradmedj-2020-139065. 40. Annweiler G, Corvaisier M, Gautier J, Dubée V, Legrand E, Sacco G, et al. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Pa- tients: The GERIA-COVID Quasi-Experimental Study. Nu- trients. 2020 Nov 2;12(11):3377. 41. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021 Mar;591(7848):92-98. 42. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V,et al; ACTT-2 Study Group Members. Bariciti- nib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807. 43. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Gio- taki SG, Gargalianos P, et al; GRECCO-19 investigators. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e2013136. 44. Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. Beneficial effects of colchicine for mo- derate to severe COVID-19: a randomised, double-blin- ded, placebo-controlled clinical trial. RMD Open. 2021 Feb;7(1):e001455. 45. Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pi- llinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv 2021.01.26.21250494. 46. Vrachatis DA, Giannopoulos GV, Giotaki SG, Raisakis K, Kossyvakis C, Iliodromitis KE, et al. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis. Hellenic J Cardiol. 2021 Jan 6:S1109-9666(20)30285-2. 47. Salah HM, Mehta JL. Meta-analysis of the Effect of Col- chicine on Mortality and Mechanical Ventilation in CO- VID-19. Am J Cardiol. 2021 Feb 19;145:170–2. 48. Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of corona- virus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021 Mar 14. 49. Lemos ACB, do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, et al. Therapeutic versus pro- phylactic anticoagulation for severe COVID-19: A rando- mized phase II clinical trial (HESACOVID). Thromb Res. 2020 Dec;196:359-366. 50. Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of In- termediate-Dose vs Standard-Dose Prophylactic Anticoa- gulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INS- PIRATION Randomized Clinical Trial. JAMA. 2021 Mar 18. 51. NIH ACTIV Trial blood thinners pauses enrollment of cri- tically ill COVID-19 patients. NIH. December 22, 2020. Available from: https://www.nih.gov/news-events/ news-releases/nih-activ-trial-blood-thinners-pau- ses-enrollment-critically-ill-covid-19-patients. Accessed [29.03.2021] 52. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phos- phate has shown apparent efficacy in treatment of CO- VID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. 53. FDA. March 28, 2020 [Internet] Available from: ht- tps://www.fda.gov/media/136534/download Accessed [05.04.2021] 54. Coronavirus (COVID-19) update: FDA revokes emergen- cy use authorization for chloroquine and hydroxychlo- roquine. FDA. June 15, 2020. [Internet] Available from: https://www.fda.gov/news-events/press-announce- ments/coronavirus-covid-19-update-fda-revokes-emer- gency-use-authorization-chloroquine-and. Accessed [05.04.2021] 55. Coronavirus (COVID-19) Update: FDA Issues Emergen- cy Use Authorization for Potential COVID-19 Treatment. FDA. May 01, 2020. [Internet] Available from: https://www. fda.gov/news-events/press-announcements/corona- virus-covid-19-update-fda-issues-emergency-use-au- thorization-potential-covid-19-treatment Accessed [10.04.2021] 56. Remdesivir es el primer tratamiento que recibe la reco- mendación de la EMA frente a Covid-19. Diariofarma. June 25, 2020 [Internet] Available from: https://www.dia- riofarma.com/2020/06/25/remdesivir-es-el-primer-tra- tamiento-que-recibe-la-recomendacion-de-la-ema-fren- te-a-covid-19. Accessed [10.04.2021] 57. Clinical management of COVID-19-World Health Organi- zation. Interim guidance. May 27, 2020. Available from: https://apps.who.int/iris/rest/bitstreams/1278777/re- trieve. Accessed [05.04.2021] 58. Guia NIH: tratamiento de COVID-19. Uso de fármacos específicos en pacientes con COVID-19. Available from: https://empendium.com/manualmibe/covid19/237133, - guias-nih-tratamiento-de-covid-19-uso-de-farma- cos-especificos-en-pacientes-con-covid-19. Accessed [08.04.2021] 59. Coronavirus Disease 2019 (COVID-19) Treatment Guideli- nes. NIH. Available from: https://www.covid 19treatment- guidelines.nih.gov/. Accessed [08.04.2021]